On April 17, 2014, the United States Food and Drug Administration (the “FDA”) issued a News Release in which it discouraged the use of laparoscopic power power morcellation for the removal of the uterus (i.e., a hysterectomy) or the removal of uterine fibroids (i.e., a myomectomy) in women because, according to the FDA’s research, the treatment can cause the spreading of certain cancers. If a woman that has a type of cancer known as a “uterine sarcoma” undergoes laparoscopic power power morcellation, the FDA has determined that the risk of spreading the cancer throughout the patient’s abdomen and pelvis is significantly elevated, and the chances of long-term survival are severely diminished. According to currently-available data, the FDA has determined that approximately 1 in 35 women undergoing a hysterectomy or myomectomy for fibroids have a uterine sarcoma.